Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib

References

• Attal M, Harousseau JL. Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract Res Clin Haematol 1999; 12:171-91; PMID:11000991; http://dx.doi.org/10.1053/beha.1999.0015
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-83; PMID:12736280; http://dx.doi.org/10.1056/NEJMoa022340
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-60; PMID:21410373; http://dx.doi.org/10.1056/NEJMra1011442
   PubMed Web of Science ®Google Scholar
• Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the international myeloma working group (IMWG). Leukemia 2014; 28:525-42; PMID:24253022; http://dx.doi.org/10.1038/leu.2013.350
   PubMed Web of Science ®Google Scholar
• Donato F, Gay F, Bringhen S, Troia R, Palumbo A. Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. Expert Opin Biol Ther 2014; 14:1127-44; PMID:24749510; http://dx.doi.org/10.1517/14712598.2014.908848
   PubMed Web of Science ®Google Scholar
• Brimnes MK, Svane IM, Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol 2006; 144:76-84; PMID:16542368; http://dx.doi.org/10.1111/j.1365-2249.2006.03037.x
   PubMed Web of Science ®Google Scholar
• Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Muller S, Buttkereit U, Opalka B, Lindemann M, Grosse-Wilde H et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47:1570-82; PMID:16966269; http://dx.doi.org/10.1080/10428190500472503
   PubMed Web of Science ®Google Scholar
• Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM, Harrison SJ, Godfrey DI, Ritchie D, Berzins SP. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol 2014; 175:49-58; PMID:24032527; http://dx.doi.org/10.1111/cei.12196
   PubMed Web of Science ®Google Scholar
• Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117:1605-13; PMID:20978269; http://dx.doi.org/10.1182/blood-2010-04-278432
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, Veloso E, Zheng Z, Westphal S, Mair R et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005; 11:1230-7; PMID:16227990; http://dx.doi.org/10.1038/nm1310
   PubMed Web of Science ®Google Scholar
• Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008; 20:504-11; PMID:18573340; http://dx.doi.org/10.1016/j.coi.2008.05.007
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008; 14:2775-84; PMID:18451245; http://dx.doi.org/10.1158/1078-0432.CCR-07-4246
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Dillon M, Song W, Leiba M, Li X-F, Burger P, Lee AI, Podar K, Hideshima T, Rice AG et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112:1329-37; PMID:17906076; http://dx.doi.org/10.1182/blood-2007-08-107292
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186:1840-8; PMID:21187443; http://dx.doi.org/10.4049/jimmunol.1003032
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar RA, Bakker JM, Lammerts-van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2014; 21(12):1–9; PMID:25398450
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96:284-90; PMID:21109694; http://dx.doi.org/10.3324/haematol.2010.030759
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30:1960-5; PMID:22291084; http://dx.doi.org/10.1200/JCO.2011.37.7069
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30:1953-9; PMID:22547589; http://dx.doi.org/10.1200/JCO.2011.37.2649
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Laubach J, Nahi H, Plesner T, Gimsing P, Hansson M, Minnema M, Lassen UN, Krejcik J, Ahmadi T et al. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). ASCO Meet Abs 2014; 32:8513
   Google Scholar
• Plesner T, Arkenau H-T, Lokhorst HM, Gimsing P, Krejcik J, Lemech CR, Minnema M, Lassen UN, Ahmadi T, Yeh H et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. ASCO Meet Abstr 2014; 32:8533
   Google Scholar
• Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62; PMID:10411544; http://dx.doi.org/10.1172/JCI6926
   PubMed Web of Science ®Google Scholar
• Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002; 99:491-504; PMID:11992538; http://dx.doi.org/10.1002/ijc.10376
   PubMed Web of Science ®Google Scholar
• Kothny-Wilkes G, Kulms D, Poppelmann B, Luger TA, Kubin M, Schwarz T. Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 1998; 273:29247-53; PMID:9786937; http://dx.doi.org/10.1074/jbc.273.44.29247
   PubMed Web of Science ®Google Scholar
• Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7:383-5; PMID:11283636; http://dx.doi.org/10.1038/86397
   PubMed Web of Science ®Google Scholar
• Menoret E, Gomez-Bougie P, Geffroy-Luseau A, Daniels S, Moreau P, Le Gouill S, Harousseau JL, Bataille R, Amiot M, Pellat-Deceunynck C. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 2006; 108:1346-52; PMID:16638930; http://dx.doi.org/10.1182/blood-2005-12-007971
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98:795-804; PMID:11468181; http://dx.doi.org/10.1182/blood.V98.3.795
   PubMed Web of Science ®Google Scholar
• Belch A, Sharma A, Spencer A, Tarantolo S, Bahlis NJ, Doval D, Gallant G, Kumm E, Klein J, Chanan-Khan AA. A multicenter randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with bortezomib in patients with relapsed/refractory multiple myeloma (MM). ASH Ann Meet Abstr 2010; 116:5031
   Google Scholar
• Straube C, Wehner R, Wendisch M, Bornhauser M, Bachmann M, Rieber EP, Schmitz M. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007; 21:1464-71; PMID:17495970; http://dx.doi.org/10.1038/sj.leu.2404734
   PubMed Web of Science ®Google Scholar
• Subklewe M, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dorken B, Pezzutto A. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 2007; 68:147-55; PMID:17349869; http://dx.doi.org/10.1016/j.humimm.2006.12.005
   PubMed Web of Science ®Google Scholar
• Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107:3575-83; PMID:16282346; http://dx.doi.org/10.1182/blood-2005-05-2118
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau J-L, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26:4784-90; PMID:18711175; http://dx.doi.org/10.1200/JCO.2007.14.9641
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000; PMID:12208752
   PubMed Web of Science ®Google Scholar
• Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 2012; 72:4562-73; PMID:22738917; http://dx.doi.org/10.1158/0008-5472.CAN-12-0487
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100:230-7; PMID:12070032; http://dx.doi.org/10.1182/blood.V100.1.230
   PubMed Web of Science ®Google Scholar
• Yang D-H, Park J-S, Jin C-J, Kang H-K, Nam J-H, Rhee J-H, Kim Y-K, Chung S-Y, Choi S-J-N, Kim H-J et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leukemia Res 2009; 33:665-70; PMID:18922577; http://dx.doi.org/10.1016/j.leukres.2008.09.006
   PubMed Web of Science ®Google Scholar
• Barreira da Silva R, Münz C. Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals. Cell Mol Life Sci 2011; 68:3505-18; PMID:21861182; http://dx.doi.org/10.1007/s00018-011-0801-8
   PubMed Web of Science ®Google Scholar
• Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010; 115:2167-76; PMID:19965656; http://dx.doi.org/10.1182/blood-2009-08-238469
   PubMed Web of Science ®Google Scholar
• Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195:335-41; PMID:11828008; http://dx.doi.org/10.1084/jem.20010934
   PubMed Web of Science ®Google Scholar
• Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: “l'union fait la force”. Blood 2005; 106:2252-8; PMID:15933055; http://dx.doi.org/10.1182/blood-2005-03-1154
   PubMed Web of Science ®Google Scholar
• Walzer T, Dalod M, Vivier E, Zitvogel L. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Exp Opin Biol Ther 2005; 5(Suppl 1):S49-59; PMID:16187940; http://dx.doi.org/10.1517/14712598.5.1.S49
   PubMedGoogle Scholar
• Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002; 195:1653-9; PMID:12070293; http://dx.doi.org/10.1084/jem.20020338
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, Steinman RM, Ravetch JV, Dhodapkar MV. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A 2005; 102:2910-5; PMID:15703291; http://dx.doi.org/10.1073/pnas.0500014102
   PubMed Web of Science ®Google Scholar
• Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 2003; 170:4069-76; PMID:12682236; http://dx.doi.org/10.4049/jimmunol.170.8.4069
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18; PMID:8145033; http://dx.doi.org/10.1084/jem.179.4.1109
   PubMed Web of Science ®Google Scholar
• Day D, Pham K, Ludford-Menting MJ, Oliaro J, Izon D, Russell SM, Gu M. A method for prolonged imaging of motile lymphocytes. Immunol Cell Biol 2009; 87:154-8; PMID:18982018; http://dx.doi.org/10.1038/icb.2008.79
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-22; PMID:10363983
   PubMed Web of Science ®Google Scholar
• Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46:673-83; PMID:10794750
   PubMed Web of Science ®Google Scholar